Phase 4 Trial Planned Comparing Semaglutide Timing After Bariatric Surgery

A Phase 4 clinical trial update dated October 5, 2026 was registered under identifier NCT07859189. The trial is titled "Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery." Its current status is listed as not yet recruiting. The study is registered as Phase 4, indicating it concerns an approved drug being studied in a post-marketing context. According to the listing, the trial aims to compare two approaches to semaglutide administration in patients who show a suboptimal clinical response one year after undergoing primary metabolic and bariatric surgery. No recruitment has begun as of the date listed, and no outcome data or results have been reported at this stage. This brief reflects only the registration details available at this time, including the trial title, phase designation, and current recruitment status. Readers should note that liraglutide itself is not the subject drug named in this particular trial record, which concerns semaglutide. For broader context on liraglutide, including its approved uses and regulatory status, readers can consult the compound overview.